This funding builds on JDRF's previous support of the work of Dr. Michael Riddell of York University and Dr. Richard Liggins of The Centre for Drug Research and Development, founding scientists behind Zucara.
Zucara is advancing a novel therapeutic approach to prevent hypoglycemia in patients with diabetes. With this new investment, the company will be in a position to advance its lead clinical drug candidate through IND-enabling studies, readying it for clinical testing beginning in 2019.
The Zucara technology is aimed at creating the first treatment to prevent dangerous low blood sugar by restoring the body's ability to counter-regulate hypoglycemia. This approach will reduce the likelihood of insulin therapy to cause hypoglycemia without affecting its efficacy.
The immediate patient benefits would include the reduced occurrence of hypoglycemia and its associated acute symptoms and effects. This in turn would allow those with T1D to better regulate their blood sugar levels with insulin, resulting in better overall health outcomes in the long term.
JDRF funds T1D research to accelerate breakthroughs to cure, prevent, and treat T1D and its complications. To accomplish this, the organization has invested more than USD2 bn in research funding since inception. It has staff and volunteers throughout the United States and at six international affiliates.
Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development and MaRS Innovation, is developing a drug therapy to prevent hypoglycemia in people with diabetes.
The company's first-in-class therapeutic is aimed at inhibiting a hormone in the pancreas called somatostatin, which does not function properly in Type 1 diabetes.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes